Gaucher disease
Conditions
Interventions
Intervention type:
Name of intervention:
Dose form / Japanese Medical Device Nomenclature:
Route of administration / Site of application:
Dose per administration:
Dosing frequency / Frequency of use:
Sponsors
Kazuya Tsuboi
Hiroshi Yamamoto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with a diagnosis of GD based on histological diagnosis, measurements of enzyme activity, and genetic testing. 2.Patients receiving treatment with imiglucerase 60 U/kg every two weeks or Velaglucerase alfa 60 U/kg every two weeks.
Exclusion criteria
Exclusion criteria: 1.Patients with osteogenic malignancy or bone metastases were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In this study, we evaluate bone lesions in Gaucher disease and the long-term efficacy of Enzyme replacement therapy on bone lesions. This prospective observational study is initiated in November 2004. ERT is performed at Nagoya Central Hospital where this study is conducted. Except for bone tissue immunostaining, all observation-tests for the study including various relevant tests, bone X-ray, bone MRI, BMD (DXA method), and blood tests are conducted in the same hospital, in addition to clinical symptoms. | — |
Countries
Japan
Contacts
Public ContactKazuya Tsuboi
Nagoya Central Hospital
Outcome results
None listed